Trial Profile

Efficacy and Safety of Tofacitinib in patients with severe active Rheumatoid Arthritis

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 15 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tofacitinib (Primary) ; Corticosteroids; Leflunomide; Methotrexate; Prednisone
Indications Rheumatoid arthritis
Focus Adverse reactions; Therapeutic Use

15 Jun 2019 Results (n=26) investigating the effect of tofacitinib on the levels of NT-proBNP during 12-Month Follow-Up, presented at the 20th Annual Congress of the European League Against Rheumatism.
17 Jun 2017 Results (n=28) evaluating the effects of tofacitinib on cardiovascular risk factors in rheumatoid arthritis patients during 12-month follow-up, presented at the 18th Annual Congress of the European League Against Rheumatism.
17 Jun 2017 Pooled results the safety and efficacy of Tofacitinib in patients from this this and one another study (n=142), presented at the 18th Annual Congress of the European League Against Rheumatism

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com